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Uremic serum effects on peripheral blood mononuclear cells and
purified T lymphocyte responses. We have studied the effects of uremic
serum on the activation state and function of normal lymphocytes in
vitro, by examining both accessory cell-dependent and accessory
cell-independent responses. Uremic serum was obtained from patients
on conservative treatment and from the same patients after they have
undergone six months of maintenance hemodialysis. Uremic serum
inhibited the proliferative responses to mitogens and to recombinant
IL-2 (rIL-2) of both peripheral blood mononuclear cells (PBMC) and
purified T cell populations. However, the responsiveness to IL-2 of
pre-formed lymphoblasts, obtained from both PBMC and purified T
cells, in the presence of uremic serum was similar to that obtained in the
presence of normal serum, or was even enhanced. Uremic serum did
not affect the cellular IL-2 receptor a (IL-2R) generation though it
inhibited significantly the release of soluble LL-2 receptor (sLL-2R) and
the production of IL-2 after mitogenic stimulation. Uremic serum from
patients after six months of hemodialysis enhanced, but did not
completely restore, proliferative responses and IL-2 production by
control PBMC. Neither IL-l nor IL-2R, which are present at elevated
concentrations in uremic serum, appeared to be responsible for serum
effects on in vitro responses of control lymphocytes. In conclusion, our
results indicate that uremic serum affects both accessory cell-mediated
and accessory cell-independent normal T cell responses. Uremic serum
inhibition of T cell proliferation is associated with down-regulation of
IL-2 synthesis by lymphocytes and the induction of an abnormal state
of activation of lymphoblasts which is further enhanced following
chronic hemodialysis.
Cellular immune responses of patients affected by end-stage
renal disease (ESRD), treated conservatively or by replacement
therapy, are impaired [1—31. The relative proportions of func-
tional T cell subsets have been reported as altered [4, 5] and
mitogenic lymphocyte responses as depressed [4, 6]. The mech-
anisms responsible for the altered T cell function have not been
elucidated. Earlier studies have shown that in uremia the
activity of suppressor cell is increased [7, 81 and that monocyte
defects have a primary role in the inhibition of T cell prolifer-
ation [9, 10]. According to others, however, replacement of
uremic monocytes by normal monocytes in culture did not
restore physiological T cell proliferation in vitro [ill. Over the
last few years a number of studies have focused on the role of
IL-2 and its cell-surface receptor in uremia-associated immu-
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nodeficiency. Production of IL-2 by lymphocytes from hemo-
dialysis patients has been reported as reduced [12] and it has
been suggested that the impairment of immune responsiveness
in uremia is due to a condition of pre-activation of T cells. Such
a pre-activation state is expressed by an elevated number of
circulating T cells bearing IL-2R on their cytoplasmic mem-
brane [12], by high plasma levels of sIL-2R [12—14], and by
increased sensitivity of T cells to exogenous IL-2 in vitro [121.
Uremic serum is likely to exert a major role in immunosuppres-
sion as described in earlier studies [15—16]. In this regard, it has
been recently shown that uremic serum inhibits accessory-cell-
dependent T cell proliferation [17]. We report here on the
effects of uremic serum on monocyte dependent and monocyte
independent T cell proliferative responses, IL-2 production and
sIL-2R release, as well as on the effects of uremic serum on the
responsiveness of resting and pre-activated control PBMC to
exogenous IL-2. Furthermore, since impairment of cellular
immunity in uremic patients has been directly linked to the
duration of hemodialysis [4] and since hemodialysis resembles a
recurrent acute phase inflammatory response, during which
activation of complement [18], cytokines [19—211 and immuno-
competent cells [18—20] occurs, we have compared the in vitro
effect, on control lymphocyte responses, of sera obtained from
uremic patients on conservative treatment and after they have
been undergone maintenance hemodialysis of six months.
Methods
Peripheral blood mononuclear cell (PBMC) preparation
Peripheral blood was obtained from healthy donors of the
New Brunswick Affiliated Hospitals' Blood Program. PBMC
were isolated by centrifugation of heparinized blood on a
Ficoll-Hypaque gradient (Pharmacia Diagnostics, Piscataway,
New Jersey, USA). Cells were subsequently washed three
times with medium RPM! 1640 (Gibco, Grand Island, New
York, USA) supplemented with penicillin/streptomycin (Gibco)
and re-suspended at a concentration of 1 x 106 cells/mI.
T cell preparation
Positive selection of CD2 + lymphocytes was performed by
using magnetizable polystyrene beads coated with a monoclo-
nal antibody specific for the CD2 antigen (Dynal Inc., Great
Neck, New York, USA). Briefly, the PBMC suspension was
mixed for 20 minutes at 4°C by tilt rotation with immunomag-
netic beads at a ratio of 1:3, respectively. To isolate the rosetted
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CD2+ cells, the test tube was kept undisturbed in a magnetic
particle concentrator for two minutes. The supernatant was
then discarded, the tube was removed from the magnet and the
Dynabeads rosetted cells were resuspended in a washing buffer
(PBS/2% FCS). This washing procedure was repeated five
times. In order to detach the beads, rosetted cells were incu-
bated in the test tube for eight hours at 37°C using a standard
culture medium (RPM! 1640/1% FCS). Following this, cells and
beads were resuspended with a pasteur pipette and detached
beads were isolated using the magnetic particle separator. Cells
prepared using immuno-magnetic beads were >98% positive for
the CD2 antigen when tested by flow cytometry.
Serum collection and preparation
Serum was separated by centrifugation of 10 ml of whole
blood and subsequent ultracentrifugation. Normal control se-
rum was obtained from healthy volunteers. Uremic serum was
obtained from end-stage renal disease patients with their in-
formed consent. Ten uremic patients were bled on the day of
their first hemodialysis session and after six months of hemo-
dialysis treatment. Five cell populations from five healthy
volunteers were each tested against two pre-hemodialysis sera,
against two post-hemodialysis sera (6 months), against two
normal control sera and against culture medium. This experi-
ment was repeated under the same conditions using the same
uremic and control sera against cells from a different donor. In
all cases samples from hemodialysis patients were obtained just
prior to the next hemodialysis session after the long stretch.
To remove IL-i, some randomly chosen serum samples from
hemodialysis patients were pipetted into 96-well flat bottomed
microtiter plates (100 pg/well). Wells had been previously
coated with a monoclonal antibody anti-IL-1f3. After two hours
samples were aspirated and, after determination of IL-lf3 con-
centration, were employed in the control experiments. The
same procedure was carried out to remove soluble IL-2R from
serum. In this case samples were obtained from both never-
dialyzed and from chronically dialyzed uremic patients. Normal
cells and normal sera were obtained from two different healthy
donors.
Flow cytometry
Quantitation of lymphocytes expressing IL-2R. PBMC, at a
concentration of 1 x 106 cells/ml, were incubated with RPM!
1640 supplemented with 10% FCS and penicillin/streptomycin
for 72 hours. Either normal serum or uremic serum (from
patients on conservative treatment or after six months of
hemodialysis) at 20% concentration was added in the medium.
Cultures were either left unstimulated or stimulated with 10
ig/ml of T cell mitogen phytohemagglutinin P (PHA; Sigma, St.
Louis, Missouri, USA). Following incubation cells were
washed and stained with a fluorescein-labeled monoclonal
antibody directed against the a chain of the IL-2R (CD25:
anti-TAC, Becton Dickinson, Mountainview, California, USA)
and analyzed by flow cytometry using a Coulter Epics Profile
cytometer. Two thousand lymphocytes were counted for each
determination.
Proliferative responses of PBMC
The proliferative PBMC responses were studied by culturing
them in the presence of either 10 g/ml of PHA or recombinant
IL-2 (provided by Cetus Inc., Emeryville, California, USA) at
concentrations of 10 and 1000 lU/mi. The culture medium
consisted of RPMI 1640 plus penicillin/streptomycin supple-
mented with either 10% fetal calf serum (FCS) alone or 10%
FCS plus 20% uremic or control human serum. PBMC (5 x l0
cells in 0.1 ml of medium) were plated in quadruplicate in
round-bottom microtiter plates (Gibco) and incubated at 37°C in
a 5% CO2 atmosphere. Mter 72 hours, 1 Ci of [H3]thymidine
([3H]TdR) was added to each well, and the cultures were
incubated for an additional six hours. Following this incubation,
the cultures were harvested using a cell harvester (Flow Labo-
ratories, McLean, Virginia, USA) and radioactivity was mea-
sured in a liquid scintillation counter (Pharmacia LKB Biotech-
nology Inc., Gaithersburg, Maryland, USA). The proliferative
responses are expressed as mean count per minute (cpm) of
quadruplicate determinations or as a stimulation index (SI)
reflecting the ratio of stimulated to unstimulated responses.
In other sets of experiments cells which had been previously
incubated for 72 hours with the culture media described above
were subsequently washed and re-cultured in standard RPM!
1640 supplemented with 10% FCS and penicillin/streptomycin.
Proliferative responses of T cells
The proliferative responses of T cells were studied by cultur-
ing them in the presence of either a combination of 10 g/ml of
PHA and 5 ng/mi of phorbolmyristic acetate ester (PMA;
Sigma), or of 10 g/ml of PHA plus 10 lU/mi of IL-2, or IL-2
alone at 10 and 100 lU/mi. The culture media and procedures
were the same as those employed for PBMC.
Responsiveness to IL-2 of pre-formed lympho blasts
PBMC and T cells were incubated for three days in the
presence of 10 g/ml of PHA (PBMC) or the combination of 10
g/ml PHA + 5 nglml of PMA (T cells) at a concentration of 1
x 106 cells/mI. Following this incubation, cells were washed
and re-cultured in microplates in the presence of 10 and 100
lU/mi of recombinant IL-2. After 72 hours, cultures were
harvested and proliferative responses were estimated by mea-
suring [H]TdR incorporation. Normal or uremic serum, at 20%
concentration, was added either in the first period of the culture
with the mitogens or in the second period with the IL-2.
IL-2 production and soluble IL-2R release
PBMC were first incubated for 72 hours in culture medium
supplemented with 20% normal or uremic serum. Following
this, incubated cells were washed and cultured with either 10
pg/ml of PHA or 10 pg/mi of PHA + 5 ng/ml of PMA. IL-2 was
measured in the supernatants of cultures of PHA/PMA-stimu-
iated PBMC by using an enzyme immunoassay for human IL-2
(Quantikine, R & D Systems Inc., Minneapolis, Minnesota,
USA). Soluble IL-2 receptor was measured in the supernatants
of cultures of PBMC stimulated with PHA by using an enzyme
immunoassay (T cell Sciences, Cambridge, Massachusetts,
USA).
Statistical analysis
Results are expressed as mean SEM unless otherwise
specified. The Wilcoxon rank sum test was employed to com-
pare independent data. The signed rank test was employed for
paired data. These non-parametric tests were chosen because
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Fig. 1. PBMC proliferative responses to stimulation with optimal
concentration of PHA (10 sg/ml). Symbols are: (LI) unstimulated; ()
PHA. Culture medium had been supplemented with human serum. 1:
control medium (10% FCS-RPMI); 2: normal serum, 3: serum of
patients affected by end-stage renal disease on conservative treatment,
4: serum of patients after 6 months of hemodialysis.
our data did not conform to a normal distribution. Differences
were considered significant when P < 0.05.
Results
Effect of uremic serum on proliferative responses of PBMC to
PHA and IL-2
PBMC were stimulated with 10 g/ml of PHA and the
proliferative responses after 72 hour culture are shown in
Figure 1. The culture medium contained either 10% FCS alone
or FCS supplemented with normal serum or uremic serum from
patients on conservative treatment and after six months of
hemodialysis. It is apparent that there is no change in lympho-
cyte response between FCS alone and normal serum. Prolifer-
ative responses to PHA were significantly impaired by the
presence of uremic serum (P < 0.002). Serum taken after six
months of hemodialysis supported a higher proliferative re-
sponse than that obtained with the serum from patients on
conservative treatment (28,829 6,243 vs. 18,575 5,329; P <
0.05).
The proliferative responses of resting lymphocytes to rIL-2
were also determined. DNA synthesis was induced by both
concentrations of rIL-2 (2,589 669 with 10 IU/ml of IL-2 and
4,842 1,044 with 100 lU/mi of rIL-2, compared to 583 66
cpm of the unstimulated cells in the presence of normal serum).
As shown in Figure 2, uremic serum inhibited [3H]TdR incor-
poration induced by both concentrations of IL-2 (P < 0.05). The
magnitude of the responses was similar with the use of serum
from patients treated conservatively or with that of dialyzed
patients.
The effect of pre-incubation with uremic serum on mitogen-
and IL-2-induced lymphocyte proliferation was examined by
incubating normal PBMC for 72 hours in culture media contain-
ing either FCS alone or FCS supplemented with normal or
uremic serum at 20% concentration. After incubation, cells
were washed and cultured in 10% FCS-RPMI medium. As
shown in Figures 3 and 4, pre-incubation with uremic serum
impaired the proliferative response to PHA (P < 0.05 vs.
normal serum) as well as responsiveness to IL-2 (P < 0.01).
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Fig. 2. PBMC proliferative responses to stimulation with 10 and 100
lU/mi of recombinant IL-2. Symbols are: (LI) unstimulated; () 10
lU/mi; () 100 IU/ml. Culture medium had been supplemented with
human serum. 1: control medium (l0%FCS-RPMI); 2: normal serum, 3:
serum of patients affected by end-stage renal disease on conservative
treatment; 4: serum of patients after 6 months of hemodialysis.
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Fig. 3. PBMC proliferative responses to stimulation with optimal
concentration of PHA (JO g/ml). Symbols are: (LI) unstimulated; ()
PHA. PBMC had been previously incubated with human serum for 72
hours and subsequently cultured in 10% FCS-RPMI culture medium. 1:
control medium (l0%FCS-RPML); 2: normal serum, 3: serum of pa-
tients affected by end-stage renal disease on conservative treatment; 4:
serum of patients after 6 months of hemodialysis.
Pre-incubation with serum from patients after six months of
regular hemodialysis treatment did not modify proliferative
responses of lymphocytes to PHA, whereas it increased the
amount of DNA synthesis in the presence of IL-2 (P <0.05 vs.
non-dialysis).
Effect of uremic serum on responsiveness to IL-2 of pre-
formed lymphoblasts
Normal PBMC were incubated for 72 hours in the presence of
PHA (10 pg/ml) and then washed and re-cultured in the pres-
ence of two different concentrations of recombinant IL-2 (10
and 100 lU/mi) or of medium alone (RPMI + 10% FCS).
Normal or uremic serum was added either in the first 72-hour
period of the culture, together with PHA, or in the second
72-hour period, together with IL-2 or the medium alone. Flow
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Fig. 4. PBMC proliferative responses to stimulation with 10 and 100
lU/mi of recombination IL-2. Symbols are: (0) unstimulated; () 10
lU/mi; (0) 100 lU/mi. PBMC had been previously incubated with
human serum for 72 hours and subsequently cultured in 10% FCS-
RPMI medium. I: control medium (l0%FCS-RPMI); 2: normal serum,
3: serum of patients affected by end-stage renal disease on conservative
treatment; 4: serum of patients after 6 months of hemodialysis.
cytometry analysis of cells pre-activated with PHA and recul-
tured in the presence of IL-2 and sera showed that 65% of the
cells were blasts (by size).
Figure 5A shows that addition of uremic serum together with
PHA inhibited significantly [3H]TdR incorporation after a total
of six days of incubation (P < 0.002). With the addition for IL-2,
lymphoblasts responded efficiently. Stimulation indices (SI),
however, were similar with normal and uremic sera. When 10
lU/mi of rIL-2 was used the SI were: non-dialysis: 3.61 1.12;
six-month dialysis: 2.39 1.11; normal serum: 2.91 1.01;
with 100 IUIm1 of rIL-2 the SI were: non-dialysis: 5.62 1.11;
six-month dialysis: 4.25 2.45; normal serum: 4.25 1.51.
Differences between non-dialysis and six-month dialysis (abso-
lute cpm and SI) were not significant.
Figure SB shows the effects of normal and uremic serum
added to the medium in the second period of culture. In this
case no inhibition of the IL-2 responsiveness of PHA lympho-
blasts by uremic serum was seen with the concentration of 100
lU/mi. In fact, the calculation of the SI shows that sensitivity to
rIL-2 of lymphoblasts cultured with uremic serum is higher than
that of lymphoblasts cultured with normal serum. When 10
lU/mI of rIL-2 were used the SI were: non-dialysis, 7.65 4.07;
six-month dialysis, 6.27 4.72; normal serum, 3.45 1.63; P <
0.05. When 100 lU/mI of rIL-2 were used the SI were: non-
dialysis, 14.79 8.86; six-month dialysis, 9.29 5.82; normal
serum, 4.06 2.18; P < 0.01. At the concentrations of 100
lU/mi of IL-2 the absolute values of DNA synthesis obtained
with uremic serum were the same as those obtained with
control medium and normal serum. The differences between
dialyzed and never dialyzed patients' sera were not statistically
significant.
Effects of uremic serum on IL-2 receptor generation
PBMC were incubated with either normal or uremic serum, in
the presence or absence of 10 g/ml of PHA. After 72 hours
cells were washed and subsequently stained with an anti-IL-2R
(a chain) monoclonal antibody (anti-TAC or anti-CD25). As
shown in Figure 6, there was no change in the percentage of
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unstimulated or PHA stimulated lymphocytes bearing the IL-
2Ra on their cytopiasmic membrane, when these were incu-
bated in the presence of serum obtained from chronic hemodi-
alysis patients.
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Fig. 5. Prolferative responses to 10 and 100 lU/mi of recombinant
IL-2 by pre-formed lymphoblast (PHA-stimulated). Symbols are: (0)
unstimulated; (0)10 lU/mI; (0)100 lU/mi. In A human serum was
added in the first 72 hour period of the culture together with PHA,
whereas in B human serum was added in the second, 3 day period of the
culture together with recombinant IL-2. 1: control medium (lO%FCS-
RPMI); 2: normal serum, 3: serum of patients affected by end-stage
renal disease on conservative treatment; 4: serum of patients after 6
months of hemodialysis.
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Fig. 6. Percentage of lymphocytes expressing the IL-2 receptor (a
chain). Symbols are: (U) unstimulated; () PHA. PBMC had been
previously incubated for 72 hours with human serum. 1: normal serum,
2: serum of patients affected by end-stage renal disease on conservative
treatment; 3: serum of patients after 6 months of hemodialysis.
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Effects of uremic serum on release of soluble IL-2R
PBMC were incubated with normal or uremic serum for 72
hours, then washed and recultured in the presence of PHA (10
jgIml) for an additional 72 hours and soluble IL-2R was
measured in the supernatant of cultures. When pre-incubated
with uremic serum, PBMC released smaller amounts of soluble
IL-2R than when incubated with normal serum (Fig. 7, P <
0.03). Incubation with serum obtained from hemodialyzed
patients was associated with the release of higher amounts of
soluble IL-2R than was the case with incubation with serum of
patients on conservative treatment. However, the difference
was not statistically significant.
Effects of uremic serum on IL-2 production
PBMC were pre-incubated with normal or uremic serum for
72 hours and then washed and recultured in the presence of
PHA and PMA. IL-2 was measured in the supernatant. As
shown in Figure 8, incubation with uremic serum strikingly
reduced the production of IL-2 by normal lymphocytes (P <
0.01). This incubation, however, was less pronounced when
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Fig. 9. T cell proliferative responses to stimulation with PHA/PMA
and PHA/IL-2. Symbols are: (D) unstimulated; () PHA + PMA; ()
PHA + IL-2 (lU/mi). Culture medium had been supplemented with
human serum. 1: control medium (l0%FCS-RPMI); 2: normal serum, 3:
serum of patients affected by end-stage renal disease on conservative
treatment; 4: serum of patients after 6 months of hemodialysis.
serum was taken from patients maintained on hemodialysis for
six months (P <0.05 vs. non-dialysis).
Effects of uremic serum on proliferative responses of purified
T cells
T cells were stimulated with either PHA and PMA, PHA and
IL-2 (10 lU/mi), or IL-2 alone in the presence or absence of
normal or uremic serum. As shown in Figure 9, proliferative
responses of T cells to PHAIPMA and to PHA/IL-2 are im-
paired by the presence of uremic serum in the culture medium.
Maximal inhibition was seen in PHAIIL-2 induced cultures (P <
0.01). Serum from patients hemodialyzed for six months shows
nearly a normal response to PHA/PMA and also did not inhibit
as much as the uremic pre-dialysis serum the responses to
PHA/IL-2. However, in absolute counts per minute the prolif-
erative responses did not reach the levels obtained with normal
serum.
The responsiveness of T cells to IL-2 is shown in Figure 10.
Uremic serum reduced significantly [3H]TdR incorporation by
normal T cells in the presence of IL-2 (P < 0.01); there was a
considerable improvement in the responses when T cells were
cultured in the presence of six-month dialysis serum (P < 0.05
vs. non-dialysis), yet this response was lower than that obtained
with normal serum (P < 0.03). Pre-incubation of T cells with
uremic serum and subsequent culture in standard 10% FCS-
RPMI gave similar results (data not shown).
Effects of uremic serum on responsiveness to recombinant
IL-2 of pre-formed T lymphoblasts.
T lymphoblasts were obtained by culturing T cells in the
presence of the combination of PHA and PMA. After 72 hours
cells were washed and cultured for an additional 72 hours in the
presence of 10 and 100 IU/ml of recombinant IL-2. Normal or
uremic serum were added either in the first period with the
mitogens, or in the second culture period with IL-2 (Fig. 1 lA
and 1 1B). Addition of uremic serum from patients on conserv-
ative treatment in the first three-day period strikingly inhibits
proliferation in response to subsequent addition of IL-2 (P <
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Fig. 7. Release of soluble IL-2R by lymphocytes after stimulation with
PHA. PBMC had been previously incubated for 72 hours with human
serum. 1: normal serum, 2: serum of patients affected by end-stage renal
disease on conservative treatment; 3: serum of patients after 6 months
of hemodialysis.
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Fig. 8. IL-2 production by lymphocytes after stimulation with PHAI
PMA. PBMC had been previously incubated for 72 hours with human
serum. 1: normal serum, 2: serum of patients affected by end-stage renal
disease on conservative treatment; 3: serum of patients after 6 months
of hemodialysis.
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Fig. 10. T cell proliferative responses to 10 and 100 lU/miof recombi-
nant IL-2. Symbols are: (El) unstimulated; () 10 lU/mi; () 100 lU/mi.
Culture medium had been supplemented with human serum. 1: control
medium (l0%FCS-RPMI); 2: normal serum, 3: serum of patients
affected by end-stage renal disease on conservative treatment; 4: serum
of patients after 6 months of hemodialysis.
0.001, Fig. hA). Absolute levels of DNA synthesis are higher
in cultures containing uremic serum of chronic hemodialysis
patients compared with those containing non-dialysis serum (P
< 0.05), though lower than with normal controls (P < 0.03).
Relative responsiveness to IL-2 (as expressed by SI), however,
is similar to that in the presence of normal serum: 1.23 0.24
(non-dialysis) and 1.41 0.30 (6-month dialysis) versus 1.37
0.36 (normal serum) with 10 IU of IL-2; 1.52 0.41 (non-
dialysis) and 1.54 0.43 (6-month dialysis) versus 1.60 0.51
(normal serum) with 100 IU of IL-2.
As shown in Figure 11B addition of non-dialysis serum in the
second period of the culture inhibits the mitogenic response (P
<0.002: non-dialysis vs. normal serum). The addition of serum
from hemodialysis patients, however, is associated with a
higher response (P < 0.05 vs. non-dialysis). The [3H]TdR
incorporation after stimulation with rIL-2 is similar or even
higher with uremic or normal serum. Accordingly, measure-
ment of SI gives higher values with uremic serum than with
normal serum: 3.53 0.54 (non-dialysis) and 3.29 0.49
(6-month dialysis) versus 1.61 0.31 (normal serum) with 10 IU
of IL-2, P < 0.01; 4.36 0.96 (non-dialysis) and 3.76 0.76(6
month dialysis) versus 2.13 0.73 (normal serum) with 100 IU
of IL-2, P < 0.02. Each different experiment with T cells
(quiescent lymphocytes or activated lymphoblasts) was con-
trolled with parallel experiments in which purified IL-i had
been added to the culture medium. Such addition did not
change the results (not shown).
Role of IL-I on immunoregulatoty properties of uremic serum
Serum from uremic patients who had been undergoing main-
tenance hemodialysis for six months contained high levels of
IL-1f3: (1,694 265 pg/mI; measured by ELISA for IL-l/3, R&D
System Inc., Minneapolis, Minnesota, USA), whereas serum
from patients on conservative treatment contained extremely
low levels of the cytokine (26.5 14 pg/mi). IL-i has a central
role in the process of T cells activation [231. Since serum from
chronic hemodialysis patients modifies some of the lymphocyte
responses, we performed control experiments in which large
amounts of IL-h had been removed from serum. Such elimina-
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Fig. 11. Proltferative responses to 10 and 100 lU/mi of recombinant
IL-2 by pre-formed highly purified T iyinphoblasts (PHA-stimulated).
Symbols are: (El) unstimulated; () 10 lU/mI, () 100 lU/mi. In A
human serum was added in the first 72-hour period of the culture
together with PHA, whereas in B human serum was added in the
second, 3 day period of the culture together with recombinant IL-2. 1:
control medium (lO%FCS-RPMI); 2: normal serum, 3: serum of pa-
tients affected by end-stage renal disease on conservative treatment; 4:
serum of patients after 6 months of hemodialysis.
tion (296 54 pg/ml of IL- 1 remaining in the samples) had no
effect on the results regardless of whether PBMC, pure T cells
or performed lymphoblasts responses were studied. As a fur-
ther control, serum from patients on conservative treatment
had been supplemented with purified IL-i at a concentration
resembling that of hemodialysis patients but no change was
observed in this case either (not shown).
Role of soluble IL-2 receptor on immunoregulatory properties
of uremic serum
Serum from both uremic patients on conservative treatment
and after six months of regular hemodialysis contained high
levels of soluble IL-2 receptor (1.496 36 and 1,369 27
units/mi, respectively; T Cell Sciences, Cambridge, Massachu-
setts, USA). The released form of the IL.-2R has been shown to
down regulate the immune response, since it can bind IL-2 [24].
In order to evaluate the possibility of a role of the high
concentrations of IL-2R in the immunosuppressive properties
of uremic serum, we performed a number of control experi-
ments in which serum had been depleted of large amounts of
soluble IL-2 receptor (225 62 U/mI of sIL-2R remaining in the
3
2
1
0
A
I InEaC0
0
2-0
C-,C
a)C
E
I
rif flU
60
50
40
30
20
10
0
80
70
60
50
40
30
20
10
0
B
I
ii
0 4
Donati et a!: Uremic serum and T cells 687
samples). Proliferative responses of both quiescent and acti-
vated lymphocytes were absolutely undistinguishable from
those obtained with uremic serum not depleted of soluble IL-2R
(not shown).
Discussion
Our study shows that uremic serum inhibits the proliferative
response to lectins of normal lymphocytes. Pre-incubation of
cells with uremic serum was also associated with reduction of
[3H]TdR incorporation and this suggests that the inhibitory
effect of uremic serum is somewhat irreversible and lasts even
when serum is washed away and cells are cultured in a normal
culture medium. Lymphocyte proliferative responses obtained
with the addition of 20% normal serum to the culture medium
were undistinguishable from those obtained with 10% FCS-
RPMI alone. This indicates that the increased protein concen-
tration in the medium per se does not alter the results. Reduced
lymphocyte proliferation in vitro in response to mitogens is a
typical finding in uremic patients [4, 6].
IL-2 has a pivotal role in T cell proliferation. It exerts its
biological effects by binding to a high-affinity receptor which
consists of two distinct polypeptide chains, a smaller IL-2
binding peptide (55 kD), which is designated as the a-chain, and
a larger peptide (75 kD) which is termed the p-chain. The a
chain of the IL-2R binds IL-2 with low-affinity and its expres-
sion has been characterized by the use of fluorescein-conju-
gated monoclonal antibodies such as the anti-TAC. The per-
centage of TAC positive lymphocyte, both unstimulated and
PHA stimulated, is not affected by uremic serum. High-affinity
receptors are able to mediate IL-2 internalization while low-
affinity are not; accordingly, only high-affinity receptor can
trigger IL-2-mediated cell proliferation [251. It has also been
shown that the concentrations of IL-2 which bind with high
affinity to the IL-2 receptors are the same as the concentrations
that promote T cell proliferation in vitro [26]. Thus T cell
proliferation in the presence of exogenous IL-2 is a good,
though indirect, index of high-affinity IL-2 receptor expression.
In an earlier study [13] we have shown that proliferation of T
cells obtained from long-term hemodialysis patients in the
presence of different concentrations of exogenous IL-2 is im-
paired. The present study provides evidence that uremic serum
can reproduce the same defect on normal PBMC both when
they are pre-incubated with such serum and when uremic serum
is added at the initiation of the culture. The expression of
high-affinity IL-2 receptors is an event that follows activation of
T cells [26]. In order to investigate whether uremic serum can
affect the process of induction of responsiveness to IL-2, we
pre-incubated quiescent lymphocytes for 72 hours in the pres-
ence of PHA (10 g/ml) and uremic serum. Following this
incubation, cells were washed and re-cultured in the presence
of different concentrations of IL-2. Proliferative responses of
cells previously stimulated with PHA and in the presence of
uremic serum in such six-day cultures were extremely low
compared to those obtained in the presence of normal serum;
the addition of IL-2, however, induced rates of proliferation
similar to those seen in the presence of normal serum. In
another set of experiments the influence of uremic serum on the
IL-2 responsiveness of pre-formed lymphocytes was studied by
adding uremic serum together with IL-2. The addition of uremic
serum after PHA stimulation inhibited DNA synthesis even
more than when the addition was made in the first period. The
addition of IL-2, however, induced a strikingly high prolifera-
tion which, with the highest concentrations of IL-2, reached the
same level (in terms of absolute [3H]TdR incorporation) as that
obtained in the presence of normal serum. These results indi-
cate that uremic serum does not suppress but rather enhances
the sensitivity to recombinant IL-2 of activated lymphocytes.
Since proliferative responses to IL-2 requires binding of IL-2 to
its receptors and its internalization [25], it is reasonable to
exclude any interference of uremic serum with those steps of
activation as well as with the next events leading to DNA
synthesis.
Our results also show that uremic serum has opposite effects
on the IL-2 responsiveness of quiescent lymphocytes and
pre-formed lymphoblasts, respectively. Resting lymphocytes
have a low sensitivity to exogenous IL-2. In this case, prolifer-
ative responses to IL-2 reflect only the weak mitogenic effect of
the cytokine and such responses are inhibited by uremic serum.
It has been shown that the number of PBMC expressing the
high-affinity IL-2 receptor after mitogenic stimulation is very
high in both normal individuals and in hemodialyzed as well as
non-hemodialyzed uremic patients, with similar cellular densi-
ties of receptors among the three groups [22]. In line with such
a finding we found that, after mitogenic stimulation, the addi-
tion of IL-2 results in high lymphocyte proliferative responses.
Our results indicate that uremic serum increases the sensitivity
of T cells to IL-2, which indirectly indicates an up-regulation of
biologically active high-affinity IL-2R. Yet, simultaneously,
uremic serum impairs lymphoblasts' ability to proliferate. Such
an explanation is consistent with the finding of low background
(mitogenic stimulation), low absolute [H]TdR incorporation
with rIL-2 but with normal or even enhanced SI. These results
are consistent with the hypothesis that uremic immunodefi-
ciency is due to a condition of pre-activation of T cells [12] and
with earlier studies in which association of immunodeficiency
with up-regulation of the IL-2R in uremia has been described
[27].
Earlier studies have shown that IL-2 production by the T
cells of uremic patients is reduced [12] and that addition of IL-2
in the cultures restores a normal proliferation of uremic lym-
phocytes in vitro [28]. The inhibition of the proliferative re-
sponse to mitogen induced by uremic serum might thus be
caused by a reduction of IL-2 production. Indeed the data
reported here show that uremic serum impairs the ability of
normal lymphocytes to produce IL-2. The soluble form of the
IL-2R is released in the circulation by activated T cells [29]. We
have demonstrated in an earlier study [13] that uremic patients
treated conservatively or by replacement treatment have strik-
ingly high levels of plasma soluble IL-2R. PHA-stimulated
lymphocytes of uremic patients, however, released very small
amounts of IL-2R in the supernatants of cell culture which
closely correlated with the poor proliferative response of ure-
mic lymphocytes to the lectin [13]. In agreement with such
results, our present study shows that uremic serum significantly
reduces the release of soluble IL-2R by PHA-stimulated normal
lymphocytes. We have shown in an earlier study that release of
soluble IL-2R is a valuable indicator of cell proliferation and
that such release is an IL-2 dependent phenomenon probably
regulated at an early stage of T cell activation. We have also
shown that release of soluble IL-2R is not correlated with the
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expression of surface low-affinity IL-2R [30]. The results of the
present study on the effects of uremic serum on release of
soluble IL-2R are in excellent agreement with those conclu-
sions: uremic serum inhibits IL-2 production, soluble IL-2R
release and proliferative responses, while it has no effect on the
expression and generation of cellular surface low-affinity IL-2R.
A number of studies have shown a defect at the monocyte
level [9, 10, 17], whereas others have shown defective T
lymphocyte responses in the presence of normal monocyte
function [11, 12]. In the present study T cell proliferative
responses to PHA/PMA were severely impaired by uremic
serum regardless of whether it was added at the initiation of the
culture or whether it was used to pre-incubate the cells. The
combination of PHAIIL-2 up-regulated DNA synthesis by nor-
mal T cells in the presence of normal serum but did not support
T cell growth in the presence of uremic serum. Responsiveness
of purified T cells to IL-2 was also depressed and the IL-2
responsiveness of pre-formed T-lymphoblasts was similar to
that of PBMC. These data indicate that uremic serum directly
inhibits T cell function in addition to inhibiting monocyte-
dependent T cell proliferation.
A number of components of uremic serum with inhibitory
effects on the immune response have been described 115, 16].
Recent studies, including ours, have shown that uremic serum
contains extremely high levels of sIL-2R [12—14]. Soluble IL-2R
might then be an inhibitory factor of uremic serum since it binds
IL-2 efficiently [20], and in the present study we examined this
possibility. The removal of a large proportion of this molecule
from serum did not affect the results and, although its removal
was not complete, the amounts of sIL-2R remaining were
similar to or lower than those present in the serum of our
normal control population (293 20 U/ml). When cells were
cultured in the presence of normal serum the results were
similar to those obtained from cell cultures in the presence of
RPMI plus FCS. Uremic serum from hemodialyzed patients
also contains large amounts of IL- 11341, which has a key role in
the process of T cell activation by inducing the IL-2R expres-
sion. Since uremic serum increases the responsiveness to
exogenous IL-2 of pre-formed lymphoblasts, we performed
control experiments in which the same serum either contained
or was largely depleted of IL- 1. Such depletion had no effects
which suggests that this cytokine has no role in the altered
immunoregulation induced by uremic serum. This conclusion is
also supported by the finding that a high responsiveness to IL-2
was seen with the use of uremic serum from non-dialysis
patients, which does not contain high levels of IL-i (26 14
pg/mI in patients vs. 14 8 pg/mI in normal controls) and also
by the finding that the addition of purified IL-I to such serum
samples did not affect results. However, since the concentra-
tions of IL-l remaining were still higher than normal, a com-
bined effect of low levels of IL-l13 and sIL-2R in the serum of
hemodialyzed patients cannot be ruled out.
The pathogenesis of the impairment of the immune response
in uremia is unclear and various explanations have been of-
fered. In this regard we have previously reported that changes
of in vitro cellular immunity are more pronounced in patients
who have been undergoing maintenance hemodialysis for
longer periods of time [4]. In order to study whether hemodi-
alysis has a role in the inhibitory effects of the uremic serum on
the immune response, we have compared here the in vitro role
of serum from uremic patients on conservative treatment and
after the same patients were regularly treated by maintenance
hemodialysis for at least six months. When present in the
culture medium, serum from chronic hemodialysis patients
enhanced proliferative responses of quiescent lymphocytes to
PHA but did not modify the responses to exogenous IL-2. On
the other hand, pre-incubation of cells with uremic hemodia-
lyzed serum enhances response to IL-2, whereas no significant
effects are seen studying responsiveness to IL-2 of pre-formed
lymphoblasts. Proliferative responses of purified T cells were
significantly higher in the presence of serum from chronic
dialysis patients and this trend was clear in all experiments.
When serum was added in the second period of the six-day
cultures, DNA synthesis by T-lymphoblasts in the presence of
IL-2 even exceeded that in the presence of normal serum.
Serum from chronic hemodialysis patients also improved the
ability of lymphocytes to produce IL-2, compared with non-
dialysis uremic serum. Soluble IL-2R release was somewhat
higher although the difference from that obtained with non-
dialysis uremic serum did not reach levels of statistical signifi-
cance. We have demonstrated that hemodialysis is effective in
improving the compromised in vitro T cell responses occurring
in uremic environment and this effect is most likely mediated by
production of higher amounts of endogenous IL-2.
The creation of an artificial uremic environment with the use
of uremic serum in culture reproduces, at least partially, in
normal cells the pattern of cellular immunity impairment seen in
uremic patients. This provides evidence for an important role of
metabolic retention of immunosuppressive molecules in the
development of uremic immunodeficiency. Furthermore, these
data indicate that hemodialysis improves the overall function of
lymphocytes suggesting a role for dialyzable, still unidentified,
fractions.
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